Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G4A | P47712 | 3/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | FBP1 | P09467 | 1/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.33 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18430567 | 1.00 | PLA2G4A (0.36) | PLA2G4AL3MBTL1FBP1NR1I2HSPA5 | |
| SCHEMBL21217035 | 1.00 | PLA2G4A (0.36) | PLA2G4AL3MBTL1FBP1NR1I2HSPA5 | |
| SCHEMBL19334597 | 1.00 | PLA2G4A (0.36) | PLA2G4AL3MBTL1FBP1NR1I2HSPA5 | |
| SCHEMBL29325457 | 1.00 | PLA2G4A (0.36) | PLA2G4AL3MBTL1FBP1NR1I2HSPA5 | |
| SCHEMBL20098093 | 0.98 | PLA2G4A (0.35) | PLA2G4AL3MBTL1FBP1NR1I2HSPA5 | |
| SCHEMBL28578071 | 0.95 | L3MBTL1 (0.34) | PLA2G4AL3MBTL1FBP1HSPA5CTSK | |
| SCHEMBL29865290 | 0.93 | NR1I2 (0.38) | PLA2G4AL3MBTL1FBP1NR1I2 | |
| SCHEMBL12193817 | 0.85 | FBP1 (0.37) | FBP1HSPA5SLC6A2SLC6A4 | |
| SCHEMBL1670553 | 0.84 | CA2 (0.39) | PLA2G4AL3MBTL1 | |
| SCHEMBL7763980 | 0.83 | PLA2G4A (0.34) | PLA2G4AL3MBTL1FBP1HSPA5CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11666578-B2 | Small molecule inhibitors of CDK12/CDK13 | THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-20230146515-A1 | MITOCHONDRIA-TARGETING PEPTIDES | STEALTH BIOTHERAPEUTICS INC. | 2023-05-11 | — | — | US | disclosed |
| US-20210186979-A1 | SMALL MOLECULE INHIBITORS OF CDK12/CDK13 | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-06-24 | — | — | US | disclosed |
| US-9676780-B2 | Piperazine-substituted [1,2,4]triazolo[1,5-C]quinazolin-5-amine compounds with A2A antagonist properties | MERCK SHARP & DOHME CORP. (US) | 2017-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210186979-A1 | SMALL MOLECULE INHIBITORS OF CDK12/CDK13 | CDK12, CDK1, CDK13 | PLA2G4A 3005/4885L3MBTL1 3053/4885FBP1 3084/4885 |
| US-11666578-B2 | Small molecule inhibitors of CDK12/CDK13 | CDK12, CDK1, CDK13 | PLA2G4A 3005/4885L3MBTL1 3053/4885FBP1 3084/4885 |
| US-20230146515-A1 | MITOCHONDRIA-TARGETING PEPTIDES | HSPE1, TFAM, TNNI3 | PLA2G4A 962/4885L3MBTL1 1122/4885FBP1 3227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.